Illumina (ILMN) closed at $213.13 on November 6, 2026, up 2.5% from the previous close, on volume of 1,918,077 shares (30-day average 2,532,812).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 21, 2026 | Strangle or Risk Reversal | 20-Nov-26240 P : 290 C | 1,500 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Notable healthcare headlines for the week: Moderna, Pfizer, and CVS Health in focus
Seeking Alpha News (Sun, 8-Nov 9:05 AM ET)
Illumina selected to help bring precision medicine into everyday healthcare in Singapore
PRNewswire (Mon, 2-Nov 8:00 PM ET)
Illumina boosts 2026 outlook after Q3 beat driven by NovaSeq X placements
Market Chameleon (Fri, 30-Oct 6:11 AM ET)
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2026
PRNewswire (Thu, 29-Oct 4:05 PM ET)
Illumina To Webcast Upcoming Investor Conference
PRNewswire (Tue, 27-Oct 4:17 PM ET)
PRNewswire (Wed, 21-Oct 9:16 AM ET)
PRNewswire (Wed, 14-Oct 9:16 AM ET)
Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026
PRNewswire (Thu, 8-Oct 4:08 PM ET)
Illumina releases SpliceAI2 to help advance rare disease research
PRNewswire (Thu, 8-Oct 9:15 AM ET)
PRNewswire (Fri, 4-Sep 7:16 PM ET)
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Illumina trades on the NASDAQ stock market under the symbol ILMN.
As of November 6, 2026, ILMN stock price climbed to $213.13 with 1,918,077 million shares trading.
ILMN has a beta of 0.81, meaning it tends to be less sensitive to market movements. ILMN has a correlation of 0.04 to the broad based SPY ETF.
ILMN has a market cap of $32.23 billion. This is considered a Large Cap stock.
Last quarter Illumina reported $1 billion in Revenue and $1.44 earnings per share. This fell short of revenue expectation by $-21 million and exceeded earnings estimates by $.08.
In the last 3 years, ILMN traded as high as $309.35 and as low as $68.70.
The top ETF exchange traded funds that ILMN belongs to (by Net Assets): VTI, VOO, VB, VBK, IVV.
ILMN has outperformed the market in the last year with a return of +76.0%, while the SPY ETF gained +10.8%. In the last 3 month period, ILMN beat the market returning +10.0%, while SPY returned -4.1%. However, in the most recent 2 weeks ILMN has underperformed the stock market by returning -20.9%, while SPY returned -3.2%.
ILMN support price is $199.75 and resistance is $216.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ILMN shares will trade within this expected range on the day.
